Steve Martin appointed CEO

Dr Steven Martin

Dr Steven Martin

Dr Steven Martin has been appointed to the position of CEO and Director of Biosyntha as of 15th July 2013, taking over from interim manager Ann Kramer. Since foundation in Jan 2012 Biosyntha has doubled both its contract research services business and its proprietary research team. The company is now expanding its laboratory facilities and strengthening its commercial position in the industrial biotechnology sector.

Steve Martin has a background in technical and commercial development of bioprocesses in the Pharmaceutical and Industrial Biotechnology sectors. He has a successful track record of building and directing cross-disciplinary teams to develop innovative products and processes and transition them quickly to market. Steve is recognised for his ability to communicate effectively to a wide audience including the public and private sectors.

In 2012, Steve founded Inspire Biotech Ltd a consultancy company set up to catalyse the growth of Industrial Biotechnology in the UK.

Steve was formerly Executive R&D Director at TMO Renewables Ltd, where he was responsible for the internal and external research programs focussed on developing their proprietary thermophilic bacterium (Geobacillus spp.) into a robust industrial platform for the production of biofuels and chemicals from waste biomass. During his tenure at TMO, Steve set up the research labs in Guildford, recruited a talented research team and helped the Company raise more than £50m in financing to transition their technology from concept to commercialisation. In addition, he was responsible for business development in China including collaborations with a number of large state-owned companies and Universities.

Prior to TMO, Steve was Head of Fermentation at Cubist Pharmaceuticals and was responsible for the UK pilot plant and the fermentation activities at two manufacturing sites in Italy. He was lead scientist on the fermentation process development and scale-up of the first-in-class lipopeptide antibiotic daptomycin (Cubicin™). Prior to this he held research management positions at TerraGen Discovery, Inc. and Xenova Discovery Ltd. He has more than 20 years industrial experience in microbial fermentation and has authored many peer-reviewed scientific papers, articles and book chapters. He received both his degree and his PhD from the University of Surrey.